Menu
Home
Log in / Register
 
Home arrow Health arrow Advances in pulmonary drug delivery
Source

CONCLUSIONS

Respiratory infections remain a global critical health challenge. Pulmonary delivery of antimicrobials via inhalation therapy has been well accepted as an alternative or adjunctive treatment for respiratory infections. Recent advances in the design of inhaler and inhaled formulation have enabled convenient nebulization and DPI products with maximized therapeutic efficacy, minimized systemic adverse effects, and improved patient acceptability. The development of intelligent inhaled antimicrobial products will continue to play a vital role against life-threatening respiratory infections.

REFERENCES

Abdelghany, S. M., D. J. Quinn, R. J. Ingram, B. F. Gilmore, R. F. Donnelly, C. C. Taggart, and C. J. Scott. 2012. Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection. International Journal of Nanomedicine 7:4053-4063.

Adi, H., P. M. Young, H.-K. Chan, H. Agus, and D. Traini. 2010. Co-spray-dried mannitol- ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. European Journal of Pharmaceutical Sciences 40(3):239-247.

Barker, A. F., L. Couch, S. B. Fiel, M. H. Gotfried, J. Ilowite, K. C. Meyer, A. O’Donnell et al. 2000. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine 162:481-485.

Birnbaum, H. G., M. Morley, P. E. Greenberg, and G. L. Colice. 2002. Economic burden of respiratory infections in an employed population. Chest 122(2):603-611.

Boucher, H. W., G. H. Talbot, D. K. Benjamin, Jr., J. Bradley, R. J. Guidos, R. N. Jones, B. E. Murray, R. A. Bonomo, D. Gilbert, and Infectious Diseases Society of America. 2013. 10 x ‘20 progress-development of new drugs active against gram-negative bacilli: An update from the IDSA. Clinical Infectious Diseases 56(12):1685-1694.

Chan, H.-K., D. Rajbhandari, P. Tang, J. D. Brannan, and P. Phipps. 2012. Safety of administering dry powder mannitol to stimulate sputum clearance in intubated intensive care patients with sputum retention: A pilot study. American Journal of Respiratory and Critical Care Medicine 185:A6809.

Chan, J. G. Y., H.-K. Chan, C. A. Prestidge, J. A. Denman, P. M. Young, and D. Traini. 2013. A novel dry powder inhalable formulation incorporating three first-line antitubercular antibiotics. European Journal of Pharmaceutics and Biopharmaceutics 83(2):285-292.

Chew, N. Y. K, P. Tang, H.-K. Chan, and J. A. Raper. 2005. How much particle surface corrugation is sufficient to improve aerosol performance of powders? Pharmaceutical Research 22(1): 148-152.

Cipolla, D. and H.-K. Chan. 2013. Inhaled antibiotics to treat lung infection. Pharmaceutical Patent Analyst 2(5):647-663.

Coates, A. L., O. Denk, K. Leung, N. Ribeiro, J. Chan, M. Green, S. Martin, M. Charron, M. Edwardes, and M. Keller. 2011. Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis. Pediatric Pulmonology 46(4):401-408.

de Boer, A. H., P. Hagedoorn, E. M. Westerman, P. P. H. Le Brun, H. G. M. Heijerman, and H. W. Frijlink. 2006. Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer®) for high powder doses. European Journal of Pharmaceutical Sciences 28(3):171-178.

de Boer, A. H., P. Hagedoorn, R. Woolhouse, and E. Wynn. 2012. Computational fluid dynamics (CFD) assisted performance evaluation of the Twincer (TM) disposable high-dose dry powder inhaler. Journal of Pharmacy and Pharmacology 64(9):1316-1325.

de Boer, A. H., P. P. H. Le Brun, H. G. van der Woude, P. Hagedoorn, H. G. M. Heijerman, and H. W. Frijlink. 2002. Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: Development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle. European Journal of Pharmaceutics and Biopharmaceutics 54(1):17-24.

Dhumal, R. S., S. V. Biradar, S. Yamamura, A. R. Paradkar, and P. York. 2008. Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability. European Journal of Pharmaceutics and Biopharmaceutics 70(1):109-115.

Edwards, D. A, J. Hanes, G. Caponetti, J. Hrkach, A. Ben-Jebria, M. L. Eskew, J. Mintzes, D. Deaver, N. Lotan, and R. Langer. 1997. Large porous particles for pulmonary drug delivery. Science 276(5320):1868-1872.

Garonzik, S. M., J. Li, V. Thamlikitkul, D. L. Paterson, S. Shoham, J. Jacob, F. P. Silveira, A. Forrest, and R. L. Nation. 2011a. Population pharmacokinetics of colistin meth- anesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrobial Agents and Chemotherapy 55(7):3284-3294.

Garonzik, S. M., J. Li, V. Thamlikitkul, D. L. Paterson, S. Shoham, J. Jacob, F. P. Silveira, A. Forrest, and R. L. Nation. 2011b. Population PK of CMS and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrobial Agents and Chemotherapy 55(7):3284-3294.

Geller, D. E., J. Weers, and S. Heuerding. 2011. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere (TM) technology. Journal of Aerosol Medicine and Pulmonary Drug Delivery 24(4):175-182.

Geller, D. E., M. W. Konstan, S. B. Noonberg, and C. Conrad. 2007. Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety. Pediatric Pulmonology 42(4):307-313.

Ghaffari, S., J. Varshosaz, A. Saadat, and F. Atyabi. 2010. Stability and antimicrobial effect of amikacin-loaded solid lipid nanoparticles. International Journal of Nanomedicine 6:35-43.

Golshahi, L., K. H. Lynch, J. J. Dennis, and W. H. Finlay. 2011. In vitro lung delivery of bacteriophages KS4-M and ФК2 using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis. Journal of Applied Microbiology 110(1):106-117.

Grasmeijer, F., P. Hagedoorn, H. W. Frijlink, and A. H. de Boer. 2012. Characterisation of high dose aerosols from dry powder inhalers. International Journal of Pharmaceutics 437(1-2):242-249.

Grumezescu, A. M., E. Andronescu, A. M. Holban, A. Ficai, D. Ficai, G. Voicu, V. Grumezescu, P. C. Balaure, and C. M. Chifiriuc. 2013. Water dispersible cross-linked magnetic chi- tosan beads for increasing the antimicrobial efficiency of aminoglycoside antibiotics. International Journal of Pharmaceutics 454(1):233-240.

Haynes, A., J. Nakamura, C. Heng, S. Heuerding, G. Thompson, and R. Malcolmson. 2010. Aerosol performance of tobramycin inhalation powder. Respiratory Drug Delivery April:25-29.

Heng, D., D. J. Cutler, H. K. Chan, J. Yun, and J. A. Raper. 2008. What is a suitable dissolution method for drug nanoparticles? Pharmaceutical Research 25(7):1696-1701.

Hodson, M. E., C. G. Gallagher, and J. R. Govan. 2002. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. European Respiratory Journal 20(3):658-664.

Hoiby, N. 2011. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Medicine 9:32.

Infectious Diseases Society of America. 2010. The 10 x ‘20 Initiative: Pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clinical Infectious Diseases 50(8):1081-1083.

Insmed. 2009. A placebo controlled, randomized, parallel cohort, safety and tolerability study of two dose levels of liposomal amikacin for inhalation (Arikace™) in patients with bronchiectasis complicated by chronic infection due to Pseudomonas aeruginosa. https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&c

d=2&cad=rja&uact=8&ved=0ahUKEwiLva3725DKAhVKJCYKHcXjCTYQFgg lMAE&url=http%3A%2F%2Fwww.insmed.com%2Fpdf%2FPub9%25209_13_09. pdf&usg=AFQjCNHUyMeCaL5_rOfNyyGx0ykYo6L9Mg&sig2=1VpVvrGWOXYj4 Z2F3VolUQ. Protocol Number: TR02-107. Accessed September 22, 2014.

Jong, T., J. Li, D. A. V. Morton, Q. T. Zhou, and I. Larson. 2015. Investigation of the changes in aerosolization behavior between the jet-milled and spray-dried colistin powders through surface energy characterization. Journal of Pharmaceutical Sciences 105(3):1156-1163.

Konstan, M. W., D. E. Geller, P. Minic, F. Brockhaus, J. Zhang, and G. Angyalosi. 2011. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial. Pediatric Pulmonology 46(3):230-238.

Kumon, M., P. C. L. Kwok, H. Adi, D. Heng, and H.-K. Chan. 2010. Can low-dose combination products for inhalation be formulated in single crystalline particles? European Journal of Pharmaceutical Sciences 40(1):16-24.

Le Brun, P. P. H., A. H. De Boer, G. P. M. Mannes, D. M. I. De Fraiture, R. W. Brimicombe, D. J. Touw, A. A. Vinks, H. W. Frijlink, and H. G. M. Heijerman. 2002. Dry powder inhalation of antibiotics in cystic fibrosis therapy: Part 2: Inhalation of a novel colistin dry powder formulation: A feasibility study in healthy volunteers and patients. European Journal of Pharmaceutics and Biopharmaceutics 54(1):25-32.

Lee, S. H., J. Teo, D. Heng, W. K. Ng, H.-K. Chan, and R. B. H. Tan. 2013. Synergistic combination dry powders for inhaled antimicrobial therapy: Formulation, characterization and in vitro evaluation. European Journal of Pharmaceutics and Biopharmaceutics 83(2):275-284.

Liang, W., P. C. Kwok, M. Y. Chow, P. Tang, A. J. Mason, H. K. Chan, and J. K. Lam. 2014. Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids. European Journal of Pharmaceutics and Biopharmaceutics 86(1):64-73.

Liang, W., M. Y. T. Chow, P. N. Lau, Q. T. Zhou, P. C. L. Kwok, G. P. H. Leung, A. J. Mason, H.-K. Chan, L. L. M. Poon, and J. K. W. Lam. 2015. Inhalable dry powder formulations of siRNA and pH-responsive peptides with antiviral activity against H1N1 influenza virus. Molecular Pharmaceutics 12(3):910-921.

Lin, Y.-W., J. Wong, L. Qu, H.-K. Chan, and Q. T. Zhou. 2015. Powder production and particle engineering for dry powder inhaler formulations. Current Pharmaceutical Design 21(27):3902-3916.

Mangal, S., F. Meiser, G. Tan, T. Gengenbach, J. Denman, M. R. Rowles, I. Larson, and D. A. V. Morton. 2015. Relationship between surface concentration of l-leucine and bulk powder properties in spray dried formulations. European Journal of Pharmaceutics and Biopharmaceutics 94:160-169.

Markou, N., S. L. Markantonis, E. Dirnitrakis, D. Panidis, E. Boutzouka, S. Karatzas, P. Rafailidis, H. Apostolakos, and G. Baltopoulos. 2008. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug- resistant, gram-negative bacilli infections: A prospective, open-label, uncontrolled study. Clinical Therapeutics 30(1):143-151.

Master, K. 1991. Spray Drying Handbook. New York: John Wiley & Sons Inc.

Matinkhoo, S., K. H. Lynch, J. J. Dennis, W. H. Finlay, and R. Vehring. 2011. Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections. Journal of Pharmaceutical Sciences 100(12):5197-5205.

McCoy, K. S., A. L. Quittner, C. M. Oermann, R. L. Gibson, G. Z. Retsch-Bogart, and A. B. Montgomery. 2008. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 178(9):921-928.

Meers, P., M. Neville, V. Malinin, A. W. Scotto, G. Sardaryan, R. Kurumunda, C. Mackinson, G. James, S. Fisher, and W. R. Perkins. 2008. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. Journal of Antimicrobial Chemotherapy 61(4):859-868.

Mitchell, J., M. Copley, Y. Sizer, T. Russell, and D. Solomon. 2012. Adapting the Abbreviated Impactor Measurement (AIM) concept to make appropriate inhaler aerosol measurements to compare with clinical data: A scoping study with the “Alberta” idealized throat (AIT) inlet. Journal of Aerosol Medicine and Pulmonary Drug Delivery 25(4):188-197.

Nikander, K., I. Prince, S. Coughlin, S. Warren, and G. Taylor. 2010. Mode of breathing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of (99m)Tc-DTPA. Journal of Aerosol Medicine and Pulmonary Drug Delivery 23(Suppl. 1):S37-S43.

Olivier, K. N., P. A. Shaw, T. S. Glaser, D. Bhattacharyya, M. Fleshner, C. C. Brewer, C. K. Zalewski, L. R. Folio et al. 2014. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Annals of the American Thoracic Society 11(1):30-35.

Ong, H. X., F. Benaouda, D. Traini, D. Cipolla, I. Gonda, M. Bebawy, B. Forbes, and P. M. Young. 2014. In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation. European Journal of Pharmaceutics and Biopharmaceutics 86(1):83-89.

Qu, L. and D. A. V. Morton. 2015. Particle engineering via mechanical dry coating in the design of pharmaceutical solid dosage forms. Current Pharmaceutical Design 21(40):5802-5814.

Rabbani, N. R. and P. C. Seville. 2005. The influence of formulation components on the aerosolisation properties of spray-dried powders. Journal of Controlled Release 110(1):130-140.

Ratjen, F., E. Rietschel, D. Kasel, R. Schwiertz, K. Starke, H. Beier, S. van Koningsbruggen, and H. Grasemann. 2006. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy 57(2):306-311.

Retsch-Bogart, G. Z., A. L. Quittner, R. L. Gibson, C. M. Oermann, K. S. McCoy, A. B. Montgomery, and P. J. Cooper. 2009. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 135(5):1223-1232.

Reychler, G., A. Keyeux, C. Cremers, C. Veriter, D. O. Rodenstein, and G. Liistro. 2004. Comparison of lung deposition in two types of nebulization: Intrapulmonary percussive ventilation vs jet nebulization. Chest 125(2):502-508.

Sandri, A. M., C. B. Landersdorfer, J. Jacob, M. M. Boniatti, M. G. Dalarosa, D. R. Falci, T. F. Behle et al. 2013. Population PK of intravenous polymyxin B in critically ill patients: Implications for selection of dosage regimens. Clinical Infectious Diseases 57(4):524-531.

Schuster, A., C. Haliburn, G. Doring, M. H. Goldman, and Group Freedom Study. 2013. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: A randomised study. Thorax 68(4):344-350.

Serisier, D. J., D. Bilton, A. De Soyza, P. J. Thompson, J. Kolbe, H. W. Greville, D. Cipolla, P. Bruinenberg, I. Gonda, and Orbit-Investigators. 2013. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): A randomised, double-blind, placebo-controlled trial. Thorax 68(9):812-817.

Stank, K. and H. Steckel. 2013. Physico-chemical characterisation of surface modified particles for inhalation. International Journal of Pharmaceutics 448(1):9-18.

Stass, H., J. Nagelschmitz, S. Willmann, H. Delesen, A. Gupta, and S. Baumann. 2013a. Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: A phase I study. Clinical Drug Investigation 33(6):419-427.

Stass, H., B. Weimann, J. Nagelschmitz, C. Rolinck-Werninghaus, and D. Staab. 2013b. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: A phase I, randomized, dose-escalation study. Clinical Therapeutics 35(10):1571—1581.

Sugianto, T.D., H. K. Chan. 2016. Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: Clinical and drug delivery perspectives. Expert Opinion on Drug Delivery 13:7-22.

Tang, P., H. K. Chan, D. Rajbhandari, and P. Phipps. 2011. Method to introduce mannitol powder to intubated patients to improve sputum clearance. Journal of Aerosol Medicine and Pulmonary Drug Delivery 24(1):1-9.

Varshosaz, J., S. Ghaffari, M. R. Khoshayand, F. Atyabi, A. J. Dehkordi, and F. Kobarfard. 2012. Optimization of freeze-drying condition of amikacin solid lipid nanoparticles using D-optimal experimental design. Pharmaceutical Development and Technology 17(2):187-194.

Vehring, R., W. R. Foss, and D. Lechuga-Ballesteros. 2007. Particle formation in spray drying. Journal of Aerosol Science 38:728-746.

Velkov, T., N. A. Rahim, Q. T. Zhou, H.-K. Chan, and J. Li. 2015. Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead. Advanced Drug Delivery Reviews 85:65-82.

Weers, J. 2015. Inhaled antimicrobial therapy—Barriers to effective treatment. Advanced Drug Delivery Reviews 85:24-43.

Westerman, E. M., A. H. De Boer, P. P. H. Le Brun, D. J. Touw, A. C. Roldaan, H. W. Frijlink, and H. G. M. Heijerman. 2007. Dry powder inhalation of colistin in cystic fibrosis patients: A single dose pilot study. Journal of Cystic Fibrosis 6(4):284-292.

WHO. May 2014. The 10 leading causes of death in the world, 2000 and 2012. who.int/media- centre/factsheets/fs310/en/. Accessed 23 August, 2016.

Yamasaki, K., P. C. L. Kwok, K. Fukushige, R. K. Prud’homme, and H.-K. Chan. 2011. Enhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former. International Journal of Pharmaceutics 420(1):34-42.

Yang, L., Y. Liu, H. Wu, Z. J. Song, N. Hoiby, S. Molin, and M. Givskov. 2012. Combating biofilms. FEMS Immunology and Medical Microbiology 65(2):146-157.

Young, P. M., J. Crapper, G. Philips, K. Sharma, H. K. Chan, and D. Traini. 2014. Overcoming dose limitations using the orbital multi-breath dry powder inhaler. Journal of Aerosol Medicine and Pulmonary Drug Delivery 27(2):138-147.

Zhou, Q. and D. Morton. 2012. Drug-lactose binding aspects in adhesive mixtures: Controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces. Advanced Drug Delivery Reviews 64(3):275-284.

Zhou, Q., B. Armstrong, I. Larson, P. J. Stewart, and D. A. V. Morton. 2010a. Effect of host particle size on the modification of powder flow behaviours for lactose monohydrate following dry coating. Dairy Science and Technology 90(2-3):237-251.

Zhou, Q., T. Gengenbach, J. A. Denman, H. H. Yu, J. Li, and H. K. Chan. 2014a. Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection. The AAPS Journal 16(1):37-47.

Zhou, Q., D. Morton, H. H. Yu, J. Jacob, J. P. Wang, J. Li, and H. K. Chan. 2013a. Colistin powders with high aerosolisation efficiency for respiratory infection: Preparation and in vitro evaluation. Journal of Pharmaceutical Sciences 102(10):3736-3747.

Zhou, Q. T., B. Armstrong, I. Larson, P. J. Stewart, and D. A. V. Morton. 2010b. Understanding the influence of powder flowability, fluidization and de-agglomeration characteristics on the aerosolization of pharmaceutical model powders. European Journal of Pharmaceutical Sciences 40(5):412-421.

Zhou, Q. T., J. A. Denman, T. Gengenbach, S. Das, L. Qu, H. Zhang, I. Larson, P. J. Stewart, and D. A. V. Morton. 2011. Characterization of the surface properties of a model pharmaceutical fine powder modified with a pharmaceutical lubricant to improve flow via a mechanical dry coating approach. Journal of Pharmaceutical Sciences 100(8):3421-3430.

Zhou, Q. T., T. Gengenbach, J. A. Denman, H. Yu Heidi, J. Li, and H. K. Chan. 2014b. Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection. The AAPS Journal 16(1):37-47.

Zhou, Q. T., L. Qu, T. Gengenbach, I. Larson, P. J. Stewart, and D. A. V. Morton. 2013b. Effect of surface coating with magnesium stearate via mechanical dry powder coating approach on the aerosol performance of micronized drug powders from dry powder inhalers. AAPS PharmSciTech 14(1):38-44.

Zhou, Q. T., P. Tang, S. S. Y. Leung, J. G. Y. Chan, and H.-K. Chan. 2014c. Emerging inhalation aerosol devices and strategies: Where are we headed? Advanced Drug Delivery Reviews 75:3-17.

Zhou, Q. T., L. Qu, I. Larson, P. J. Stewart, and D. Morton. 2010c. Improving aerosolization of drug powders by reducing powder intrinsic cohesion via a mechanical dry coating approach. International Journal of Pharmaceutics 394(1-2):50-59.

 
Source
Found a mistake? Please highlight the word and press Shift + Enter  
< Prev   CONTENTS   Next >
 
Subjects
Accounting
Business & Finance
Communication
Computer Science
Economics
Education
Engineering
Environment
Geography
Health
History
Language & Literature
Law
Management
Marketing
Mathematics
Political science
Philosophy
Psychology
Religion
Sociology
Travel